October 8, 2025
________________________________________________________________________________________________
Kindling Bio is delighted to announce our move into the Innovation Gateway, a world-leading hub dedicated to accelerating cancer research and innovation.
This strategic milestone marks a major step forward in establishing our research operations. The move embeds Kindling Bio into a world-leading centre of excellence for paediatric cancer research, providing access to state-of-the-art facilities, specialist equipment, and a vibrant community of leading cancer researchers and clinicians within the London Cancer Hub.
The Innovation Gateway is a flagship facility for high-potential life sciences companies, situated within the ambitious London Cancer Hub, home to The Institute for Cancer Research and The Royal Marsden, where plans have been submitted by Aviva Capital Partners and Socius for a c. 1 million sq ft development of lab and R&D facilities. The Innovation Gateway provides the infrastructure and collaborative environment needed to advance cancer research and fast-track the discovery of new treatments.
For Kindling Bio, joining this prestigious community offers the ideal foundation to scale our cancer gene therapy platform in an environment that will meaningfully accelerate our development towards the clinic.
“The Innovation Gateway provides the perfect environment for us to advance our research programme, offering flexible and affordable lab space as well as the opportunity to access specialist equipment and collaborate with researchers and clinicians at the Institute of Cancer Research and Royal Marsden. Having previously undertaken postdoctoral research at the ICR, it is exciting to once again be mixing with the incredibly dedicated teams and to be part of the dynamic and growing research cluster at the London Cancer Hub.” — Dr. Jeff Drew, Co-founder of Kindling Bio
What's Next for Kindling Bio
This move marks a critical step in Kindling Bio’s mission to put children first in cancer immunotherapy. With these new capabilities, our team will focus on advancing our cancer gene therapy platform through key preclinical studies, developing our manufacturing processes, and strengthening collaborations across the cancer research ecosystem.
Our new home at the Innovation Gateway represents an important step toward bringing our vision of curative cancer gene therapy closer to the children and families who need it most.
About Kindling Bio
Kindling Bio is a biotechnology company advancing paediatric-led next-generation cancer gene therapies designed to reprogram tumour biology and harness the power of children’s immune systems to fight a wide range of tumours.
